{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:28:56Z","timestamp":1793046536184,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jad.2023.11.025","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T11:32:27Z","timestamp":1699702347000},"page":"223-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"special_numbering":"C","title":["Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database"],"prefix":"10.1016","volume":"346","author":[{"given":"Ying","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2023.11.025_bb0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation[J]","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.jad.2023.11.025_bb0010","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management[J]","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"key":"10.1016\/j.jad.2023.11.025_bb0015","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jad.2019.02.056","article-title":"A pilot study of brexpiprazole for bipolar depression[J]","volume":"249","author":"Brown","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.11.025_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2023.935872","article-title":"Dopamine receptor agonists mechanism of actions on glucose lowering and their connections with prolactin actions[J]","volume":"4","author":"Chien","year":"2023","journal-title":"Front. Clin. Diabetes Healthc."},{"issue":"6","key":"10.1016\/j.jad.2023.11.025_bb0025","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/JCP.0000000000001297","article-title":"Effect of brexpiprazole on prolactin and sexual functioning: an analysis of short-and long-term study data in major depressive disorder[J]","volume":"40","author":"Clayton","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.jad.2023.11.025_bb0030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1192\/bja.2021.49","article-title":"Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine[J]","volume":"29","author":"Cookson","year":"2023","journal-title":"BJPsych Adv."},{"issue":"9","key":"10.1016\/j.jad.2023.11.025_bb0035","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.euroneuro.2019.06.008","article-title":"Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone[J]","volume":"29","author":"Corponi","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2023.11.025_bb0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/03007995.2020.1841618","article-title":"The burden of disease in early schizophrenia\u2013a systematic literature review[J]","volume":"37","author":"Crespo-Facorro","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"10.1016\/j.jad.2023.11.025_bb0045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.9740\/mhc.2017.09.207","article-title":"Brexpiprazole: a review of a new treatment option for schizophrenia and major depressive disorder[J]","volume":"7","author":"Diefenderfer","year":"2017","journal-title":"Ment. Health Clin."},{"issue":"3","key":"10.1016\/j.jad.2023.11.025_bb0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system[J]","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am. Stat."},{"issue":"2","key":"10.1016\/j.jad.2023.11.025_bb0055","first-page":"69","article-title":"Brexpiprazole for the treatment of schizophrenia and major depressive disorder: a comprehensive review of pharmacological considerations in clinical practice[J]","volume":"51","author":"Edinoff","year":"2021","journal-title":"Psychopharmacol. Bull."},{"issue":"6","key":"10.1016\/j.jad.2023.11.025_bb0060","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports[J]","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"16","key":"10.1016\/j.jad.2023.11.025_bb0065","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1080\/14656566.2019.1654457","article-title":"Brexpiprazole for treatment-resistant major depressive disorder[J]","volume":"20","author":"Fornaro","year":"2019","journal-title":"Expert. Opin. Pharmacother."},{"issue":"12","key":"10.1016\/j.jad.2023.11.025_bb0070","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.3390\/ijms23126571","article-title":"Brexpiprazole reduces 5-HT7 receptor function on astroglial transmission systems[J]","volume":"23","author":"Fukuyama","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jad.2023.11.025_bb0075","doi-asserted-by":"crossref","DOI":"10.1017\/S2045796019000891","article-title":"Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017[J]","volume":"29","author":"He","year":"2020","journal-title":"Epidemiol. Psychiatr. Sci."},{"issue":"1","key":"10.1016\/j.jad.2023.11.025_bb0080","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/ijms22010373","article-title":"The role of estrogen receptors and their signaling across psychiatric disorders[J]","volume":"22","author":"Hwang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.jad.2023.11.025_bb0085","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1176\/appi.ajp.2020.20081212","article-title":"Anticholinergic medication burden\u2013associated cognitive impairment in schizophrenia[J]","volume":"178","author":"Joshi","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.11.025_bb0090","series-title":"International Public Health and the Burden of Diseases[J]. Evaluating International Public Health Issues: Critical Reflections on Diseases and Disasters, Policies and Practices","first-page":"1","author":"Mabuza","year":"2020"},{"key":"10.1016\/j.jad.2023.11.025_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.1082375","article-title":"Enhancement of adenosine A2A signaling improves dopamine D2 receptor antagonist-induced dyskinesia via \u03b2-arrestin signaling[J]","volume":"16","author":"Nagaoka","year":"2023","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jad.2023.11.025_bb0100","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jad.2020.07.046","article-title":"Prevalence of perinatal depression and its determinants in Mainland China: a systematic review and meta-analysis[J]","volume":"277","author":"Nisar","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"8","key":"10.1016\/j.jad.2023.11.025_bb0105","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio[J]","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"S1","key":"10.1016\/j.jad.2023.11.025_bb0110","doi-asserted-by":"crossref","first-page":"S795","DOI":"10.1192\/j.eurpsy.2022.2056","article-title":"The Navigate First Psychosis Program: a balance between the medical and recovery models in the debate about long term prophylactic antipsychotics. Mission impossible?[J]","volume":"65","author":"Sharony","year":"2022","journal-title":"Eur. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2023.11.025_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41687-021-00380-4","article-title":"Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews[J]","volume":"5","author":"Weiss","year":"2021","journal-title":"J. Patient-Rep. Outcomes"},{"key":"10.1016\/j.jad.2023.11.025_bb0120","article-title":"Comparative safety signal assessment of hospitalization associated with the use of atypical antipsychotics[J]","volume":"13","author":"Yunusa","year":"2022","journal-title":"Front. Psychol."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503272301385X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503272301385X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:11:38Z","timestamp":1759032698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016503272301385X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":24,"alternative-id":["S016503272301385X"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2023.11.025","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2023.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}